Shares of Interpace Diagnostics Group (NASDAQ: IDXG) are trading 7% higher this morning after the company said it has extended its agreement with LabCorp (NYSE: LH) for an additional two years, until January 2019. The company originally entered into the agreement with the global life sciences company, LabCorp, in January 2016. Per the original agreement, LabCorp agreed to exclusively offer Interpace’s molecular tests, ThyGenX® and ThyraMIR®. “We are pleased to renew and extend our agreement with LabCorp, a world leader in healthcare diagnostics. Execution of the initial phase of our arrangement has proven successful and we are encouraged by recent developments that clearly facilitate the opportunities to work even more closely together in the future,” Interpace Diagnostics president and CEO Jack E. Stover stated in the news release.
To view the full press release, visit: http://nnw.fm/p9ArO
About Interpace Diagnostics Group, Inc.
Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services to evaluate the risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The company currently has three commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics’ mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, visit www.interpacediagnostics.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
